Evidence map›Paper›PMID 37747314›Full record

ArticleJournal of applied biomedicine2023

The molecular targets of Kangai injection in gastric cancer by in silico network pharmacology approach and experiment confirmation.

Yongjun Qiu, Sujun Huang, Minfang Zhu

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in Journal of applied biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yongjun QiuShangRao People's Hospital, Department of Pharmacy, ShangRao, Jiangxi 334000, China.
Sujun HuangShangRao People's Hospital, Department of Pharmacy, ShangRao, Jiangxi 334000, China.
Minfang ZhuShangRao People's Hospital, Department of Pharmacy, ShangRao, Jiangxi 334000, China.
Shangrao Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to identify the phytochemical constituents that could target gastric cancer in Kangai injection using a network pharmacology-based approach.

methodsProtein-protein interactions (PPI), Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted utilizing String and OmicShare tools. In the in vitro experiments, the related mRNA and protein levels were assessed via real-time quantitative polymerase chain reaction and Western blotting, respectively. Cell proliferation was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay.

resultsKangai injection comprises several compounds, which target multiple substrates and pathways related to gastric cancer. The PPI and Gene Ontology analyses revealed that tumor necrosis factor (TNF) was a hub gene. KEGG pathway enrichment analysis indicated that the the TNF pathway was significantly enriched. Kangai injection decreased the mRNA levels of TNFR2, TRAF2, PI3K, AKT, and IκBα and inhibited the phosphorylation of PI3K, AKT, and IκBα phosphorylations. Kangai injection inhibited cell proliferation, while TNFR2 overexpression or treatment with the PI3K activator 740 Y-P partially restored it.

conclusionKangai injection operates through multiple targets and pathways in gastric cancer, with the TNFR2/PI3K/AKT/NF-κB pathway playing a crucial role in its mechanism against gastric cancer.

Indexed as

Stomach NeoplasmsHumansNetwork PharmacologyNF-KappaB Inhibitor alphaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaNF-KappaB Inhibitor alphaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alphaGastric cancerKangai injectionNetwork pharmacologyTNF pathway

Identifiers

PMID37747314
OpenAlexW4386956738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.